Bacterial Conjunctivitis Clinical Trial
Official title:
Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers
To compare the pharmacokinetic behavior of azithromycin eye drops in the tear with the original azithromycin eye drops, and evaluate the release behavior of both in the eye.
Status | Recruiting |
Enrollment | 56 |
Est. completion date | December 30, 2017 |
Est. primary completion date | October 30, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - 18 to 65 years old, male or female; - BMI in the range of 19 to 28; - eyes corrected visual acuity should be = 1.0, intraocular pressure, slit lamp and fundus examination were normal, tear secretion function is normal; - Good compliance and voluntarily signed consent. Exclusion Criteria: - Have eye disease or systemic disease; - physical examination, laboratory tests, ECG and chest X-ray examination abnormalities and has clinical significance; - HBsAg, anti-HCV and HIV positive; - those who used eye drops two weeks before the test and who used any dosage form of azithromycin; - known to azithromycin or macrolide-related varieties of allergies or serious adverse reactions; - need to wear contact lenses during the test; - history of internal surgery or laser surgery history; - participated in other drug clinical trials in the past three months; - pregnant women and lactating women, or in the growth period without taking effective contraceptive measures, menstrual period women; - mental illness or alcohol, history of drug abuse or inability to collaborate; - Any other circumstances that the investigators consider are unfit to participate in this study. |
Country | Name | City | State |
---|---|---|---|
China | Beijing Tongren Hospital | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Beijing Tongren Hospital | Panacea Technology Co.,Ltd, Zhuhai Essex Bio-Pharmaceutical Company Limited |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | AUC0-t | The tear samples were taken at 8 time points after administration,10 minutes,half hour,2 hours,4 hours,8 hours,12 hours,24 hours,36 hours,The AUC of the test drug and the control drug was calculated at the average concentration of each point | The tear samples were taken at 8 time points after administration,10 minutes,half hour,2 hours,4 hours,8 hours,12 hours,24 hours,36 hours | |
Secondary | Cmax | The tear samples were taken at 8 time points after administration,10 minutes,half hour,2 hours,4 hours,8 hours,12 hours,24 hours,36 hours,The Cmax of the test drug and the control drug was calculated at the average concentration of each point | The tear samples were taken at 8 time points after administration,10 minutes,half hour,2 hours,4 hours,8 hours,12 hours,24 hours,36 hours | |
Secondary | AE | compared the laboratory test values before and after treatment,according to the study drug use, calculate the number of cases, the number of cases and the incidence of adverse reactions. | from the ICF signed to the end of the trial,through study completion, an average of 1 year | |
Secondary | SAE | Any serious adverse events that occur during the clinical study, whether or not related to the drug should be collected. | from the ICF signed to the end of the trial,through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00565123 -
Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial Conjunctivitis
|
Phase 2/Phase 3 | |
Completed |
NCT00972777 -
Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis
|
Phase 2/Phase 3 | |
Completed |
NCT00798577 -
Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment
|
Phase 4 | |
Completed |
NCT00759148 -
Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis
|
Phase 3 | |
Completed |
NCT00331916 -
AL-15469A for the Treatment of Bacterial Conjunctivitis
|
Phase 3 | |
Completed |
NCT02432807 -
Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis
|
Phase 3 | |
Completed |
NCT01573910 -
An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients
|
Phase 3 | |
Terminated |
NCT01330355 -
Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis
|
Phase 3 | |
Completed |
NCT00332293 -
AL-15469A for the Treatment of Bacterial Conjunctivitis
|
Phase 3 | |
Completed |
NCT03004924 -
Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo
|
Phase 3 | |
Completed |
NCT02980523 -
Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)
|
Phase 2 | |
Completed |
NCT01877694 -
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
|
Phase 2 | |
Completed |
NCT01175590 -
Safety of Besivanceā¢ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle
|
Phase 3 | |
Completed |
NCT00464438 -
A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis
|
Phase 4 | |
Completed |
NCT00312338 -
Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora
|
Phase 4 | |
Completed |
NCT00105534 -
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)
|
Phase 3 | |
Completed |
NCT00105469 -
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)
|
Phase 3 | |
Recruiting |
NCT06363292 -
Study to Evaluate the Safety and Tolerability of PRO-231 Ophthalmic Solution Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects.
|
Phase 1 | |
Withdrawn |
NCT01238783 -
Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis
|
Phase 2 | |
Terminated |
NCT01740388 -
Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis
|
Phase 3 |